AOD9604 Research Information
Growth Hormone Fragment
For Metabolic & Lipolysis Research
️ Important: This information is for educational and research purposes only. Always consult with a qualified healthcare professional before use.
Contents
What is AOD9604?
AOD9604 is a synthetic peptide fragment of the C-terminus of human growth hormone (Tyr-hGH177-191) that harbors the fat-reducing activity of hGH without its negative effects. It is a hexadecapeptide consisting of 16 amino acids with the sequence YLRIVQCRSVEGSCGF.
Unlike full-length growth hormone, AOD9604 does not act via IGF-1 and has no effect on insulin resistance or glucose intolerance, making it a promising research compound for metabolic studies. AOD9604 is available in pen and freeze-dried vial formulations for research purposes.
How AOD9604 Works
AOD9604 works through multiple mechanisms to influence fat metabolism:
Lipolysis
Stimulates the breakdown of fat in adipocytes
Lipogenesis Inhibition
Inhibits the transformation of non-fat materials into body fat
Non-IGF-1 Action
Does not act via IGF-1, avoiding growth hormone side effects
AOD9604 directly stimulates lipolysis and inhibits lipogenesis without affecting appetite or blood sugar levels.
Research Applications
Weight Management
Investigating fat reduction and body composition in obesity research
Lipid Metabolism
Studying fatty acid oxidation and lipid regulation pathways
Cartilage & Bone
Exploring regenerative properties and cartilage repair
Metabolic Research
Investigating glucose metabolism and insulin sensitivity
Clinical Studies
Phase 2b Trial (METAOD005)
- 300 obese patients received oral AOD9604 (1, 5, 10, 20 or 30 mg) or placebo daily for 12 weeks
- The 1mg dose group lost an average of 2.8 kg, more than triple the placebo group (0.8 kg)
- Rate of weight loss was maintained throughout the treatment period
Safety Profile
- No effect on serum IGF-1 levels, confirming non-IGF-1 action
- No anti-AOD9604 antibodies detected in any patients
- No negative effects on carbohydrate metabolism or insulin resistance
- Safety profile indistinguishable from placebo
Interactive Dosing Guide
Select your vial size and dose to see the corresponding volume, clicks, dosing frequency, and how many doses per vial:
️ Step 1: Select Your Vial Size
Step 2: Select Your Dose
Vial Size
5mg Vial
Selected Dose
0.25 mg
Doses per Vial
20 doses
Pen Clicks
15 clicks
Volume
0.15 mL
Protocol Level
Level 1 (Starting)
Recommended Schedule
Daily - Loading Phase
️ Do not change your dose unless advised by a qualified professional.
Protocol Level Summary
Based on clinical research protocols: 0.25-2 mg daily, typically fasted in the morning.
| Protocol Level | Target Dose | Frequency | 5mg Clicks | 10mg Clicks | Who It\'s For |
|---|---|---|---|---|---|
| Level 1 (Starting) | 0.25 mg | Daily | 15 clicks | 7.5 clicks | New users, first 2 weeks |
| Level 2 (Standard) | 0.5 mg | Daily | 30 clicks | 15 clicks | After 2 weeks, maintenance |
| Level 3 (Advanced) | 1 mg | Daily | 60 clicks | 30 clicks | If more response needed |
| Level 4 (Maximum) | 2 mg | Daily | 120 clicks | 60 clicks | Experienced users only |
️ Do not change your dose unless advised by a qualified professional.
Vial Users (Insulin Syringe)
Add 3mL of bacteriostatic water to your freeze-dried vial and mix gently. After reconstitution, use the table below to draw your dose:
Vial Size
5mg vial with 3mL bac water
| Dose | Frequency | Units on Syringe | Volume (mL) | Protocol Level |
|---|
️ Always use a new sterile needle and syringe for each injection.
️ Safety & Precautions
AOD9604 has shown a very good safety and tolerability profile indistinguishable from placebo in clinical trials. It does not result in any of the adverse effects associated with full-length hGH treatment.
- No effect on serum IGF-1 levels
- No negative effects on carbohydrate metabolism or insulin resistance
- No anti-AOD9604 antibodies detected
- No dose-limiting toxicities or serious adverse events reported
Do not use if you:
- Are allergic to AOD9604 or any ingredients
- Are pregnant or breastfeeding
- Have pre-existing medical conditions (consult a healthcare professional first)
️ Warning: If you experience severe allergic reactions, difficulty breathing, or signs of anaphylaxis, seek immediate medical help.
References
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15.
- Herd et al. Phase 2b trial of AOD9604 in 300 obese patients. 2005.
- FDA Evaluation of AOD-9604 for 503A Bulks List. 2024.
This information is for educational and research purposes only. Always consult with a qualified healthcare professional.
Last updated: July 2026